Pharmaceutical

J&J asserts its place in atopic dermatitis space with Yellow Jersey acquisition

J&J gains Phase II ready NM26, a bispecific antibody in development for the treatment of atopic dermatitis.

Jul 12, 2024 - 04:00
J&J asserts its place in atopic dermatitis space with Yellow Jersey acquisition
J&J gains Phase II ready NM26, a bispecific antibody in development for the treatment of atopic dermatitis.
Read the original article

Tags:

Previous Article

BARDA and Tiba Biotech link to develop ‘flu therapeutics

Next Article

Merz wins $185m bid for bankrupt Acorda assets and increases US workforce by 50%

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Rona Therapeutics gains Series A+ funds for siRNA pipeline expansion

Rona Therapeutics gains Series A+ funds for siRNA pipel...

Jul 20, 2024

STAT+: Longer treatment gave better liver outcomes for MASH patients, Akero drug study shows

STAT+: Longer treatment gave better liver outcomes for ...

Mar 4, 2024

STAT+: Travere kidney drug narrowly fails confirmatory trial following FDA approval

STAT+: Travere kidney drug narrowly fails confirmatory ...

Sep 22, 2023